CLINICAL DATA: A-H: ELEVATED PROSTATE, PROSTATE

[A] LEFT BASE: Atypical Small Acinar Proliferation, Suspicious for Adenocarcinoma, See Note

[B] LEFT LATERAL: Prostatic adenocarcinoma
   Gleason 3 + 4 = 7  
   Measuring up to 8 mm in greatest dimension
   Adenocarcinoma occupies 56% of surface area of core biopsy
   Adenocarcinoma present in 2 of 2 core(s)

[C] LEFT MID: Prostatic adenocarcinoma
   Gleason 3 + 3 = 6
   Measuring up to 2.5 mm in greatest dimension
   Adenocarcinoma occupies 6% of surface area of core biopsy
   Adenocarcinoma present in 1 of 2 core(s)

[D] LEFT APEX: Prostatic adenocarcinoma
   Gleason 3 + 3 = 6
   Measuring up to 0.5 mm in greatest dimension
   Adenocarcinoma occupies 2% of surface area of core biopsy
   Adenocarcinoma present in 1 of 1 core(s)

[E] RIGHT BASE: Prostatic adenocarcinoma
   Gleason 4 + 5 = 9
   Measuring up to 14.5 mm in greatest dimension
   Adenocarcinoma occupies 100% of surface area of core biopsy
   Adenocarcinoma present in 1 of 1 core(s)
   See Note

[F] RIGHT LATERAL: Prostatic adenocarcinoma
   Gleason 4 + 5 = 9
   Measuring up to 14 mm in greatest dimension
   Adenocarcinoma occupies 78% of surface area of core biopsy
   Adenocarcinoma present in 2 of 2 core(s)
   See Note

[G] RIGHT MID: Prostatic adenocarcinoma
   Gleason 4 + 3 = 7
   Measuring up to 5 mm in greatest dimension
   Adenocarcinoma occupies 41% of surface area of core biopsy
   Adenocarcinoma present in 2 of 2 core(s)
   See Note

[H] RIGHT APEX: Prostatic adenocarcinoma
   Gleason 3 + 3 = 6
   Measuring up to 0.5 mm in greatest dimension
   Adenocarcinoma occupies 2% of surface area of core biopsy
   Adenocarcinoma present in 1 of 1 core(s)
Patient: PATIENT, TEST
Age: 73 (08/16/39) Pathology #: DPS-13-13454
Acct#: 27806 Sex: MALE
Doctor: DOCTOR, TEST
Date Obtained: 08/12/2013
Date Received: 08/12/2013

CC:

---

**Diagnostic Map**

**BASE**

[A] LEF T BASE

[B] LEFT LATERAL

[C] LEFT MID

[D] LEFT APEX

[E] RIGHT BASE

[F] RIGHT LATERAL

[G] RIGHT MID

[H] RIGHT APEX

---

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Fixative</th>
<th>Gross Description</th>
<th>Cassettes</th>
<th>Patient ID Confirmed</th>
<th>Site Match</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A] LEFT BASE</td>
<td>AZF</td>
<td>Spec Len</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[cm]</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>[B] LEFT LATERAL</td>
<td>AZF</td>
<td>1.3 &amp; 1.2</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>[C] LEFT MID</td>
<td>AZF</td>
<td>1.6 &amp; 1.5</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>[D] LEFT APEX</td>
<td>AZF</td>
<td>1.4</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>[E] RIGHT BASE</td>
<td>AZF</td>
<td>1.5</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>[F] RIGHT LATERAL</td>
<td>AZF</td>
<td>1.5 &amp; 1.3</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>[G] RIGHT MID</td>
<td>AZF</td>
<td>1.5 &amp; 1.4</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>[H] RIGHT APEX</td>
<td>AZF</td>
<td>1.7</td>
<td>1</td>
<td>Y</td>
<td>Y</td>
</tr>
</tbody>
</table>
NOTE: A message for Dr. TEST regarding the diagnosis of adenocarcinoma was left for him with contact on 08/15/2013, at 3:30 PM. The slides for specimens B and E were also examined by my colleague Dr. Kai Ni, who is in essential agreement.

[A] LEFT BASE atypical small acinar proliferation with associated high grade prostatic intraepithelial neoplasia. A 2nd, deeper level slide was prepared, although the small gland atypia is best seen on the initial slide.

MICROSCOPIC DESCRIPTION:
B) Carcinoma involves combined 14 mm out of combined core length of 25 mm, involves approximately 56 % of biopsy by the linear measure and surface area.
C) Carcinoma involves 2.5 mm out of combined core length of 30 mm, involves approximately 8 % of biopsy by the linear measure and 6% of surface area.
D) Carcinoma involves 0.5 mm out of combined core length of 13 mm, involves approximately 4 % of biopsy by the linear measure and approximately 2% surface area.
E) Carcinoma involves 14.5 mm out of combined core length of 14.5 mm, involves 100 % of biopsy by the linear measure and surface area.
F) Carcinoma involves combined 21 mm out of combined core length of 27 mm, involves approximately 78 % of biopsy by the linear measure and surface area.
G) Carcinoma involves combined 9 mm out of combined core length of 22 mm, involves approximately 41 % of biopsy by the linear measure and surface area.
H) Carcinoma involves 0.5 mm out of core length of 17 mm, involves approximately 3 % of biopsy by the linear measure and 2% of surface area.

The test(s) that are reported here were developed and the performance characteristics determined by Central Histology Facility of Diagnostic Pathology Medical Group, Inc. They may not have been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined that such clearance or approval is not necessary. These test(s) are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing. The appropriate positive and negative controls were used for each immunohistochemical and/or ISH stain.

Final Diagnosis performed by N. Keith McMurry, M.D.
Electronically signed 08/13/2013